Keep On Keep Up Bladder Health: Co-creating and Testing a Self-management Technological Solution for Ageing Well

NCT ID: NCT06583733

Last Updated: 2025-03-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-24

Study Completion Date

2028-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

KOKU Bladder aims to develop and test an evidence based digital health program with behavior change techniques to improve bladder health of adults aged 50 and over. A novel module embedded in the approved app "Keep-on-Keep-up" (KOKU) will be co-created with end-users, researchers, health professionals, and stakeholders through a participatory and appreciative action and reflection methodology. After a comprehensive literature review and consultation with 4-6 experts, 6 focus groups will be undertaken in Kaunas(Lithuanian), Catalonia (Spain) and Manchester (UK) to co-create the contents of the module. Data will be analyzed using thematic analysis. Gamification and the Honeycomb model for user experience will be followed to achieve an appropriate technological solution that will be tested through a randomized controlled trial with at least 120 individuals. A mixed methods approach (quantitative/qualitative analysis) will be used to assess the feasibility and acceptability of the program. Open data and science, gender and ethical aspects, as well as a risk management plan are considered. A plan for communication, dissemination, exploitation of results will be considered. KOKU Bladder will be highly scalable and will have wide reach and impact. This proposal is in line with EU policy initiatives on Active and Healthy Ageing (bladder health and continence will be promoted), targeting aspects such as eHealth, Innovation and Digital Care Transformation, by supporting users to demand more responsive and integrated care programs for chronic conditions and enhancing self-management strategies, independence and health intelligence.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Phase I (month-M1-3): Prepare and submit protocol to Ethics Committee, conduct an updated review of the on eHealth solutions to manage UI using BCTs (e.g. training, education) that have been designed or tested in older adults, and establish contact with the Lithuanian, Spanish and UK participating institutions. Phase1 is dedicated to the management of the project throughout its duration.

Phase II (M2-5): Consultation with 4-6 experts on Badder Health (BH) and/or behavioral interventions. Develop a first iteration of the eHealth method and module.

Conduct an initial online focus group with 10-12 co-creators of UK to explore their perceived acceptability and feasibility and preferences for the eHealth program (concept development through co-creation).

Develop a first iteration of the eHealth method and module (concept development) - by Reason Digital (tech company in Manchester)

Phase III (M6-14): Organize, conduct and analyze 5 more focus group (2 in Lithuania, 1 UK and 2 Spain) with 10-12 co-creators each (community-dwelling people aged 50+ of both genders with different physical conditions and UI, health professionals and stakeholders with different backgrounds) to explore their perceived acceptability and feasibility and preferences for the eHealth program (concept development through co-creation). Secondment in University of Manchester.

Phase IV (M14-M20): Further develop the eHealth module (concept development) - by Reason Digital (tech company in Manchester)

Phase V (M21-36): Multicenter two-armed feasibility RCT study with at least 120 participants (WP3). Participants will be randomized to a control (recommendations for self- managing urinary symptoms) or intervention (KOKU Bladder) group.

Phase VI: Early and open communication and dissemination (WP4). Analysis of results.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urinary Incontinence in Old Age

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

120 individuals will be simple randomised to a control (recommendations for self- managing urinary symptoms) or intervention (KOKU Bladder) group. It is anticipated that the multicomponent intervention will last 12 weeks and consist of health education, pelvic floor muscle exercises and BC techniques but this may vary according to the co-creation process. Measures will be assessed at baseline and end of intervention.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Usually, in physiotherapist studies it is very difficult to do blinding, because the patients can do some physical activity or exercise. In this trial, participants blinding will not be possible because the patients know what treatment they do, they should do the different exercises with app or with a HB information. Also, it is necessary to do face-to-face assessment for the physiotherapist.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

control group

The control group which will receive recommendations for self- managing urinary symptoms.

There will be at least 60 participants (men and women mixed) distributed in 3 countries. It is anticipated that the multicomponent intervention will last 12 weeks.

After the intervention we will collect the results with a mixed (qualitative and quantitative) approach.

Group Type ACTIVE_COMPARATOR

recommendations

Intervention Type BEHAVIORAL

In this intervention the participants will receive recommendations for self- managing urinary symptoms, which they must follow for 12 weeks.

After the intervention we will collect the results with a mixed (qualitative and quantitative) approach. Qualitative information will be recorded and analysed through thematic analysis, and quantitative data will be collected with tests and questionnaires.

intervention group

The intervention group, which will receive the treatment with KOKU Bladder. There will be at least 60 participants (men and women mixed) distributed in 3 countries. It is anticipated that the multicomponent intervention will last 12 weeks.

After the intervention we will collect the results with a mixed (qualitative and quantitative) approach.

Group Type EXPERIMENTAL

KOKU Bladder

Intervention Type BEHAVIORAL

In this intervention the participants will receive treatment with the KOKU app ( based digital health program with behavior change techniques to improve bladder health ) for 12 weeks.

After the intervention we will collect the results with a mixed (qualitative and quantitative) approach. Qualitative information will be recorded and analysed through thematic analysis, and quantitative data will be collected with tests and questionnaires.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

KOKU Bladder

In this intervention the participants will receive treatment with the KOKU app ( based digital health program with behavior change techniques to improve bladder health ) for 12 weeks.

After the intervention we will collect the results with a mixed (qualitative and quantitative) approach. Qualitative information will be recorded and analysed through thematic analysis, and quantitative data will be collected with tests and questionnaires.

Intervention Type BEHAVIORAL

recommendations

In this intervention the participants will receive recommendations for self- managing urinary symptoms, which they must follow for 12 weeks.

After the intervention we will collect the results with a mixed (qualitative and quantitative) approach. Qualitative information will be recorded and analysed through thematic analysis, and quantitative data will be collected with tests and questionnaires.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥50 (range used in the literature covering the late-life process, including prostate issues and the perimenopause period)
* Self-reported UI (at least 1 leakage/month)
* Ability to read and understand the national languages
* Have a mobile phone/tablet
* Sign informed consent.

Exclusion Criteria

* Red-flag symptoms (e.g., bleeding)
* Unstable health conditions.
Minimum Eligible Age

50 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital Universitari Santa Maria de Lleida (GSS)

UNKNOWN

Sponsor Role collaborator

Institut de Recerca i Innovació en Ciències de la Vida i de la Salut a la Catalunya Central (IRIS)

UNKNOWN

Sponsor Role collaborator

University of Manchester

OTHER

Sponsor Role collaborator

Research Council of Lithuania

OTHER

Sponsor Role collaborator

Lithuanian Sports University

OTHER

Sponsor Role collaborator

Agencia Gestió Ajuts Universitaris i Recerca

UNKNOWN

Sponsor Role collaborator

Consorci Hospitalari de Vic (CHV)

UNKNOWN

Sponsor Role collaborator

University of Vic - Central University of Catalonia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Javier Jerez Roig

Professor, Head of research group on Methodology, Methods, Models and Outcomes of Health and Social Science (M3O)

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jerez-Roig, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Vic-Central University of Catalonia; Lithuanian Sports University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Lithuanian Sports University

Kaunas, , Lithuania

Site Status RECRUITING

Hospital Santa Maria

Lleida, , Spain

Site Status RECRUITING

Hospital Consortium of Vic

Vic, , Spain

Site Status RECRUITING

University of Manchester

Manchester, , United Kingdom

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Lithuania Spain United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Javier Jerez-Roig, Professor, PhD

Role: CONTACT

+34 93 881 60 25

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Marius Brazaitis, PhD, Professor

Role: primary

8-670-59637

Oscar Águila, PhD student

Role: primary

973 72 72 22

Eva Borralleras-Fumaña

Role: primary

Emma Stanmore, PhD

Role: primary

+44 (0) 161 306 600

References

Explore related publications, articles, or registry entries linked to this study.

Jerez-Roig J, Aguila-Gimeno O, Brazaitis M, Solianik R, Karkauskiene E, Jarutiene L, Fuente-Vidal A, Borralleras-Fumana E, Gasteiger N, Stanmore E. Co-creating and testing a self-management digital solution for bladder health and urinary continence among people aged 50 and over: protocol for the international KOKU Bladder project. BMJ Open. 2025 Sep 11;15(9):e100487. doi: 10.1136/bmjopen-2025-100487.

Reference Type DERIVED
PMID: 40940057 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KOKU Bladder

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.